医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Abcam Establishes New Direct Service for Australia and New Zealand

2014年08月12日 PM05:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England

Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has established a direct service to Australia and New Zealand. The move signifies the importance of this region and Abcam’s focus on providing the best products and services to accelerate the pace of researchers’ scientific discoveries.

The new service enables customers in Australia and New Zealand to order their research tools directly from Abcam rather than through a distributor. These customers will also benefit from direct technical support, and delivery times reduced by up to 50% from order to delivery.

Philippe Cotrel, Commercial Director, Abcam, said: “I’m delighted that we can offer an enhanced service to our customers in Australia and New Zealand. A direct service will enable us to develop closer relationships with our customers, and ensure we are fully meeting their research needs.”

Abcam’s experienced technical and customer support teams and in-house manufacturing facilities provide researchers worldwide with high-performance products that they can trust, such as RabMAb® primaries.

To find out more, please visit www.abcam.com

About Abcam

Abcam plc is a global leader in the supply of innovative protein research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company’s catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com

CONTACT

Abcam
Francesca Axe
T: +44 (0) 1223 696000
or
Media
enquiries

Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T:
+44 (0) 7787 502 947

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表